|
イハラ トシコ
Toshiko Ito-Ihara
猪原 登志子 所属 川崎医科大学 医学部 応用医学 先端医療開発学 職種 教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. |
| 掲載誌名 | 正式名：Nephron. Clinical practice 略 称：Nephron Clin Pract ISSNコード：16602110/16602110 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 102(1),pp.c35-42 |
| 著者・共著者 | Toshiko Ito-Ihara, Takahiko Ono, Fumiaki Nogaki, Katsuo Suyama, Mari Tanaka, Satomi Yonemoto, Atsushi Fukatsu, Toru Kita, Kazuo Suzuki, Eri Muso |
| 発行年月 | 2006 |
| 概要 | BACKGROUND:To determine whether intravenous immunoglobulin (IVIg) can control disease activity in patients with myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated rapidly progressive glomerulonephritis (RPGN).METHODS:Twelve patients with serologically and histologically confirmed MPO-ANCA-associated RPGN (7 men, 5 women; mean age 71 +/- 3 years) received IVIg (400 mg/kg/day) alone for 5 days. The effects of IVIg were evaluated by white blood cell counts, serum C-reactive protein levels, Birmingham Vasculitis Activity Score, rate of change in reciprocal creatinine (1/Cre), and plasma tumor necrosis factor-alpha levels after IVIg administration. Corticosteroids with or without cyclophosphamide were commenced after IVIg.RESULTS:After IVIg treatment, a significant decrease was observed in white blood cell count (p < 0.05), C-reactive protein values (p < 0.001), and Birmingham Vasculitis Activity Score (p < 0.001) concomitant with the amelioration of systemic symptoms. The rate of change in 1/Cre significantly improved (p < 0.05). Plasma tumor necrosis factor-alpha levels that were significantly elevated in patients before IVIg compared with normal controls (p < 0.0001), rapidly declined after IVIg with a significant reduction (p < 0.05). Three months post-treatment with IVIg, all patients showed improvement of disease without serious infectious complications.CONCLUSION:IVIg is a potential component of remission induction therapy for patients with MPO-ANCA-associated RPGN. |
| DOI | 10.1159/000088313 |
| PMID | 16174989 |